A B S T R A C T The rise in plasma triglyceride (TG) levels associated with estrogen administration has been thought to arise from impaired clearance because of the uniform suppression of post-heparin lipolytic activity (PHLA). Recently PHLA has been shown to consist of two activities: hepatic TG lipase and extrahepatic lipoprotein lipase (LPL). To determine whether estrogen might induce a selective decline in one of these activities, both hepatic TG lipase and extrahepatic LPL were measured in postheparin plasma from 13 normal women before and after 2 wk of treatment with ethinyl estradiol (1 ,ug/kg per day). Hepatic TG lipase and extrahepatic LPL were determined by two techniques: (a) separation by heparin-Sepharose column chromatography, and (b) selective inhibition with specific antibodies to post-heparin hepatic TG lipase and milk LPL. Estrogen uniformly depressed hepatic TG lipase as measured by affinity column (-68±12%, mean±SD, P < 0.001) or antibody inhibition (-63±11%, P < 0.001). Extrahepatic LPL was not significantly changed by affinity column (-22±40%) or antibody inhibition (-3+42%). Direct measurement of adipose tissue LPL from buttock fat biopsies also showed no systematic change in the activated form of LPL measured as heparin-elutable LPL (+64+164%) or in the tissue form of LPL measured in extracts of acetone-ether powders (+21±77%). The change in hepatic TG lipase correlated with the change in PHLA (r = 0.969, P < 0.01). However, neither the change in PHLA nor hepatic TG lipase correlated with the in- 
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INTRODUCTION
Estrogens and estrogen-containing oral contraceptives elevate triglyceride (TG)1 levels in normal women (1) and may also aggravate pre-existing hypertriglyceridemia, sometimes producing marked hyperlipidemia (2) and, occasionally, a complication of hypertriglyceridemia such as pancreatitis (3) (4) (5) .
The mechanism of this effect may relate to impaired TG removal, increased TG synthesis, or both acting synergistically. Studying TG turnover in humans, Kekki and Nikkila (6), Glueck et al. (7), Kissebah et al. (8) , and Hazzard et al. (9) have independently suggested that the hypertriglyceridemia associated with estrogen therapy is due to increased TG production. However, studies in rats by Hamosh and Hamosh (10) and Kim (13) . However, despite the depressed PHLA during estrogen treatment, oral (14) and intravenous (15) fat tolerance remain normal.
These discrepancies have led to further investigation to explain the decrease in PHLA associated with estrogens. Since it has recently been shown that heparin releases into plasma not only extrahepatic LPL but also hepatic TG lipase, both of which are measured in the PHLA assay (16) , one possibility might be that there is a differential suppression of one of the triglyceride lipases within total PHLA. It has been shown that hepatic TG lipase and extrahepatic LPL are distinguishable by the differential requirement of extrahepatic LPL for the C-II apolipoprotein co-factor (17) , its inhibition by sodium chloride and protamine sulfate (16) , their differing salt elution patterns from heparin-Sepharose affinity columns (18) , and their selective inhibition by specific antibodies (19, 20 (Table I) . Identical studies were performed on day 5 of their menstrual cycles (i.e., the day menses ended) and on day 19 (after 14 days of estrogen), each subject thus serving as her own control. The subjects were on ad libitum diets during the study. 12 of the 13 subjects experienced a slight weight gain (mean change of 1.2±1 kg) during estrogen treatment, similar to previous shortterm studies with oral contraceptives (12) . No subject had taken estrogens or been pregnant for at least 1 yr before participation in this study.
Antecutibal venous blood was drawn for TG analysis (22) of whole plasma and of ultracentrifugally isolated d < 1.006, very low density lipoproteins (VLDL) (23) after an overnight, 12-h fast. An adipose tissue biopsy was then aspirated from the buttock for LPL determination and adipose cell measurement (see below). Intravenous heparin (The Upjohn Co., Kalamazoo, Mich.) (380 U/M2) was administered and blood drawn after 10 min for determination of total PHLA and separation of post-heparin lipolytic activities. Since it has been suggested (20) (24) . The two measurements of total PHLA were highly intercorrelated (Spearman's rank correlation coefficient, r, = 0.816, n = 26, P < 0.001).
Antibody inhibition studies. Selective measurement of post-heparin extrahepatic LPL was determined by the method of Huttunen et al. (20) .2 Post-heparin plasma (10 1,u) and hepatic TG lipase antibody (diluted 1:2 with normal rabbit serum) were incubated for 2 h at 4°C and the remaining extrahepatic LPL activity then measured in the usual PHLA assay system. Similarly, selective measurement of post-heparin hepatic TG lipase was determined in the PHLA assay after incubation with 10 ,lA milk LPL antibody (19) . All post-heparin plasma activities from each subject before and during estrogen were assayed with the same preparation of substrate. Incubation of post-heparin plasma with both hepatic TG lipase antibody and milk LPL antibody inhibited 95-100% of the total lipolytic activity.
Adipose tissue LPL determination. Subcutaneous buttock adipose tissue biopsy was performed by the method of Hirsch and Goldrick (25) and fat cell diameter was measured from a fixed frozen section of adipose tissue by 2 Using specific antisera kindly given by Doctors Christian Ehnholm, Jussi Huttunen, and Esko Nikkila. Goldrick (27) and fat cell weight was obtained by multiplying the cell volumne by the specific gravity of triglyceride. (26) . Measurement of LPL activity as the heparinelutable LPL and acetone ether-extracted LPL was performed as previously described (28) . Heparin-Sepharose chromatography. Heparin was covalently bound to Sepharose 4B by the method of Iverius (29) . Each post-heparin plasma sample (4 ml) was applied to heparin-Sepharose columns (diameter = 1 cm, height = 4 cm) previously equilibrated with 5 mM sodium barbital buffer (pH 7.4) containing 0.15 M NaCl. The heparinSepharose columns were washed with 15 ml of the equilibration buffer and developed in 2-3 h with a linear gradient (80 ml) from 0.15 to 
RESULTS
TG levels and PHLA (Table I) . During estrogen administration fasting plasma TG levels increased in 12 of the 13 subjects; the mean increase for the group was 76+12% (P < 0.001). Before estrogen treatment total PHLA varied from 88 to 259 nmol FFA/ml per min (mean 159±64 nmol FFA/ml per ruin) without and from 92 to 501 nmol FFA/ml per min (mean 247±140 nmol FFA/ml per min) with incuibation with normal rabbit serum. During estrogen treatment total PHLA decreased in all subjects regardless of assay method (-58+12%, P < 0.001; -48±18%, P < 0.001, respectively) (Fig. 1) . There was no significant correlation between the increase in TG and the decrease in PHLA.
Hepatic TG lipase (Table I , Fig. 1 ). Before estrogen treatment hepatic TG lipase represented 73±+-6% of the activity eluted from heparin-Sepharose, Peak I (Fig. 2) HEPATIC TRIGLYCERIDE LIPASE measured during antibody inhibition of extrahepatic LPL. During estrogen treatme-nt hepatic TG lipase decreased in all subjects both measured by heparinSepharose column chromatography (-68+12%, P < 0.001, n = 11) and antibody inhibition (-63±11%, P < 0.001, n = 13). The decrease in PHLA during estrogen therapy was strongly correlated with the decline in hepatic TG lipase measured either by heparin-Sepharose column chromatography (r = 0.834, P < 0.01, n = 11) or antibody inhibition (r = 0.939, P < 0.01, n = 13) (Fig. 3) . The decrease in hepatic TG lipase measured by the affinity column correlated with the decrease in hepatic TG lipase determined by antibody inhibition (r, = 0.745, P < 0.01, n = 11).
Extrahepatic LPL (Table I , Fig. 1 ). Before estrogen, extrahepatic LPL represented 27±6% of the activity eluted from heparin-Sepharose, Peak II (Fig. 2) , and 30± 14% of the total PHLA when measured during antibody inhibition of hepatic TG lipase. Extrahepatic LPL responded variably to estrogen when measured either by heparin-Sepharose column chromatography (+29 to -59%) or by antibody inhibition (+92 to -54%) with no significant net change (-22±40%, n = 11, NS; -3±43%, n = 13, NS, respectively). The decrease in PHLA was not correlated with the changes in extrahepatic LPL measured by either technique (affinity column: r = 0.429, n = 11; antibody inhibition: r = 0.455, n = 13) (Fig. 3) . The change in extrahepatic LPL measured by the affinity column was not significantly correlated with the change measured by antibody inhibition.
Adipose tissue LPL. The change in adipose tissue LPL during estrogen administration was studied in 12 subjects. Before estrogen adipose tissue, heparinelutable LPL was 3.8±2. 4 were not significant. The changes in adipose tissue heparin-elutable LPL were significantly correlated with the changes in post-heparin extrahepatic LPL by antibody inhibition (r, = 0.622, P < 0.05, n = 12) but not by affinity column. TG level and TG lipases. A significant correlation was found between the changes in extrahepatic LPL as measured by antibody inhibition and the increase in plasma TG (r8 = -0.600, P < 0.05, n = 13) or VLDL-TG (r, = -0.626, P < 0.05, n = 13 (35) TG (8) , and lipolysis of endogenous TG man as compared to normal levels in uremic (36) trin infusion (9), do not reveal impaired or hypothyroid (37, 38) rats. It is clear from the 1 during estrogen (7, 9) or oral contra-present studies, however, that premenopausal 8) therapy. The present studies examine women do not respond to the usual doses of estroity of a selective suppression in one of gens employed in oral contraceptive or postmenoises within total PHLA and resolve this pausal treatment with a major and consistent decrease in adipose tissue LPL. ine in PHLA observed in this group of Despite the marked decline in plasma hepatic ing estrogen therapy was strongly corre-TG lipase during estrogen demonstrated in the selective decrease in hepatic TG lipase. present studies, it is important to emphasize that sured as Peak I by heparin-Sepharose estrogen might induce a change in the hepatic bind-)matography, the decrease in PHLA vs. ing of TG lipase vis-a-vis heparin rather than a true 606 D. Applebaum 
